Načítá se...
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
BACKGROUND: In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain...
Uloženo v:
| Vydáno v: | Pharmacoeconomics |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4901121/ https://ncbi.nlm.nih.gov/pubmed/27067724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-016-0405-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|